Eli Lilly and Innovent agree Verzenios commercialisation deal in China

Eli Lilly and Company has entered into an agreement with Innovent Biologics for the commercialisation of Verzenios in mainland China. Verzenios is a CDK4 and 6 inhibitor that has received approval in China for several indications related to breast cancer. Verzenios indicated for the treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer. Credit: Peakstock/Shutterstock.com. Eli Lilly and Company has entered into an agreement with Innovent Biologics for the commercialisation of Verzenios (abemaciclib) in mainland China. Under this agreement, Innovent will handle the marketing, distribution and promotion of the product within the region, while Eli Lilly will continue to…

Source: Pharmaceutical Technology